FeRx targets MCT (Magnetic Targeted Carrier) method at GI (gastrointestinal) diseases:
This article was originally published in Clinica
Executive Summary
Preclinical results have suggested that FeRx' magnetic field-based drug delivery technique is a feasible method for delivering compounds to the gastrointestinal (GI) tract, the San Diego, California firm has reported. The Magnetic Targeted Carrier (MTC) technique may help treat GI diseases, such as inflammatory bowl disease and cancerous tumours of the oesophagus, stomach and colon, via an intra-luminal route of administration. FeRx has previously demonstrated delivery of MTCs via intra-arterial and intra-vesical routes of administration, possibly leading to the treatment of a variety of solid tumours, including those of the liver and bladder (see Clinica No 1004, p 24).
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.